Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Integrated Biosciences has joined Illumina Ventures Labs to accelerate the development of novel therapeutics targeting the transcriptome.
This partnership merges Integrated Biosciences' AI/ML-enabled drug discovery with Illumina's sequencing technologies.
The collaboration aims to discover small molecule therapeutics for age-related diseases by altering RNA expression and DNA modifications.
Felix Wong, Ph.D., co-founder of Integrated Biosciences, states that the partnership will generate large-scale datasets to map and alter cell states, targeting age-related diseases.
Ron Mazumder, Ph.D., Partner at Illumina Ventures, emphasizes the investment's potential to unlock new therapeutic candidates and modalities.
Illumina (NASDAQ: ILMN) announced the addition of Anna Richo to its Board of Directors, following shareholder approval at the annual meeting on May 16, 2024.
Richo brings over 30 years of global experience in legal, compliance, and regulatory roles, having served in senior positions at Cargill, UCB, Amgen, and Baxter Healthcare.
Illumina's CEO, Jacob Thaysen, highlighted Richo's expertise in biotechnology, biopharmaceutical, and medtech industries, which will aid in navigating the complexities of the company’s global operations.
Richo also holds director positions at Exelon, the Cargill Foundation, DePaul University, and Children's Minnesota Governance Board, and possesses degrees from Cornell University and DePaul University College of Law.
Illumina announced that its executives will be participating in Bernstein's 40th Annual Strategic Decisions Conference on May 29, 2024. The event will feature a fireside chat at 6:00am Pacific Time (9:00am Eastern Time). The webcast can be accessed via the Investor Info section of the Illumina website, with a replay available for 30 days post-event.
GRAIL, a healthcare company focused on early cancer detection, will host a virtual Capital Markets Day to discuss growth drivers for its Galleri multi-cancer early detection test. Illumina plans to divest GRAIL by the end of Q2 2024, making GRAIL a publicly traded company on Nasdaq under the ticker 'GRAL'.
Illumina, Inc. (NASDAQ: ILMN) has filed a Form 10 registration statement with the SEC for the divestiture of GRAIL. The filing includes detailed financial and business information about GRAIL. Illumina aims to finalize the divestiture terms by the end of Q2 2024. GRAIL will host a virtual Capital Markets Day on May 13, 2024, to discuss its multi-cancer early detection test and business strategy.
Illumina, Inc. (NASDAQ: ILMN) will participate in the RBC 2024 Global Healthcare Conference on May 14, 2024, with a fireside chat at 5:30am Pacific Time. The webcast can be accessed on the company's website, with a replay available for 30 days post-event.
Illumina reported financial results for Q1 2024, with core revenue at $1.06 billion, a 2% decrease from Q1 2023. GAAP operating margin was 11.0% and non-GAAP operating margin was 20.6%. Revenue decreased by 1% to $1.08 billion. GAAP diluted loss per share was ($0.79), while non-GAAP diluted earnings per share were $0.09. Illumina aims to divest GRAIL by end of Q2 2024, with a funding commitment of $1 billion in a capital markets transaction.
In celebration of DNA Day, Illumina in Cambridge, United Kingdom, hosted 150 students for hands-on science activities, inspiring young scientists to pursue careers in STEM. HRH The Princess Royal visited the event, emphasizing the importance of genomics and STEM education. The Future Is Bright initiative, promoting global genomic literacy, engages 100,000 learners annually, aiming to reach 5 million by 2030.
Summary not available.
Summary not available.